Who
Christopher Viehbacher
Director
Company insider
Files Form 4 as: Director, Braveheart Bio; President and CEO, Biogen.
In numbers
- Trades disclosed
- 29
- Buys
- 1
- Sells
- 0
- Bought
- $3.0M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Dec 2022
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $1.5M83,333 at $18.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $1.5M83,333 at $18.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,015 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,015 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —9,008 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $876K4,356 at $201.18 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —15,453 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,008 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,453 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $1.3M6,624 at $201.18 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,008 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,453 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —9,008 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $876K4,356 at $201.18 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —15,453 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $1.3M6,624 at $201.18 | filing |
| 1 Dec 2025filed 3 Dec 2025 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,040 at $0.00 | filing |
| 1 Dec 2025filed 3 Dec 2025 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —7,040 at $0.00 | filing |
News
Braveheart Bio (NASDAQ:BRVE) Stock Price Down 7.6% – Here's WhyBRVE · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Christopher Viehbacher; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.